Enterprise record

Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:b7501c6c-b71e-410c-9417-edc16acc3e24Version: public-1As of: unavailable

18 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 3 claims
    • Legal Name: Atea Pharmaceuticals, Inc. · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026

  2. Atea Pharmaceuticals, Inc. DEF 14A 2025-04-29

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 24, 2026

    Supports 9 claims
    • Leadership Role: Arthur Kirsch: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Barbara Duncan: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Bruce W. Polsky, MD, MACP, FIDSA: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Bruno Lucidi: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Franklin Berger: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Howard H. Berman, PhD: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Jean-Pierre Sommadossi, PhD: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Jerome Adams, MD, MPH: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Polly A. Murphy, DVM, PhD: Director · Claim reviewed: Sep 30, 2026

  3. AVIR 10-K executive officers

    sec filing · Source published: Mar 5, 2026 · Retrieved: May 14, 2026

    Supports 6 claims
    • Leadership Role: Andrea Corcoran: Chief Financial Officer, Executive Vice President, Legal and Secretary · Claim reviewed: Sep 30, 2026
    • Leadership Role: Janet Hammond, M.D., Ph.D.: Chief Development Officer · Claim reviewed: Sep 30, 2026
    • Leadership Role: Jean-Pierre Sommadossi, Ph.D.: President and Chief Executive Officer and Chairman of the Board of Directors · Claim reviewed: Sep 30, 2026
    • Leadership Role: John Vavricka: Chief Commercial Officer · Claim reviewed: Sep 30, 2026
    • Leadership Role: Maria Arantxa Horga, M.D.: Chief Medical Officer · Claim reviewed: Sep 30, 2026
    • Leadership Role: Wayne Foster: Executive Vice President and Chief Accounting Officer · Claim reviewed: Sep 30, 2026